Combining RAIT and immune-based therapies to overcome resistance in cancer? Combining RAIT and immune-based therapies to overcome resistance in cancer? - Archive ouverte HAL Access content directly
Book Sections Year : 2018

Combining RAIT and immune-based therapies to overcome resistance in cancer? Combining RAIT and immune-based therapies to overcome resistance in cancer?

(1) , (1) , (1) , (2) , (1) , (1, 3)
1
2
3

Abstract

Radiation therapy has long been considered as immunosuppressive; therefore its impact on the immune system and other aspects which could be involved in raising efficient antitumor immune responses has been neglected. However, the recent demonstration of the immunogenic properties of ionizing radiation is rapidly modifying the radiation oncology field, and it also opens new and promising perspectives for the development and improvement of radioimmunotherapy. In this chapter, we first review the immunogenic properties of irradiation before discussing available evidence of the benefits of radiation therapy and immunotherapy combinations in the context of lymphoma.
Fichier principal
Vignette du fichier
GuillouxChapLivre2019Eq13.pdf (341.1 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-02338494 , version 1 (30-10-2019)

Identifiers

Cite

Jean-Baptiste Gorin, Jérémie Ménager, Yannick Guilloux, Jean-François Chatal, Joëlle Gaschet, et al.. Combining RAIT and immune-based therapies to overcome resistance in cancer? Combining RAIT and immune-based therapies to overcome resistance in cancer?. Resistance to Ibritumomab in Lymphoma, 18, pp 119-137, 2018, ⟨10.1007/978-3-319-78238-6_9⟩. ⟨inserm-02338494⟩
38 View
100 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More